Literature DB >> 10875828

Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London.

A Schrag1, Y Ben-Shlomo, N P Quinn.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10875828      PMCID： PMC27420          DOI： 10.1136/bmj.321.7252.21

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Neurological disease in an English city.

Authors:  M Brewis; D C Poskanzer; C Rolland; H Miller
Journal:  Acta Neurol Scand       Date:  1966       Impact factor: 3.209

2.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.

Authors:  A Schrag; Y Ben-Shlomo; N P Quinn
Journal:  Lancet       Date:  1999-11-20       Impact factor: 79.321

3.  Parkinson's disease epidemiology in the Northampton District, England, 1992.

Authors:  R L Sutcliffe; J R Meara
Journal:  Acta Neurol Scand       Date:  1995-12       Impact factor: 3.209

4.  Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability.

Authors:  R L Sutcliffe; R Prior; B Mawby; W J McQuillan
Journal:  Acta Neurol Scand       Date:  1985-10       Impact factor: 3.209

5.  Parkinson's disease in a Scottish city.

Authors:  W J Mutch; I Dingwall-Fordyce; A W Downie; J G Paterson; S K Roy
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-22
  5 in total
  58 in total

1.  Who should look after people with Parkinson's disease?

Authors:  Rajendra Kale; Matthew Menken
Journal:  BMJ       Date:  2004-01-10

2.  Gender and the Parkinson's disease phenotype.

Authors:  Yasuhiko Baba; John D Putzke; Nathaniel R Whaley; Zbigniew K Wszolek; Ryan J Uitti
Journal:  J Neurol       Date:  2005-09-12       Impact factor: 4.849

Review 3.  Neurodegenerative disorders: Parkinson's disease and Huntington's disease.

Authors:  S M Hague; S Klaffke; O Bandmann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

4.  Ten steps to identify atypical parkinsonism.

Authors:  W F Abdo; G F Borm; M Munneke; M M Verbeek; R A J Esselink; B R Bloem
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-07-17       Impact factor: 10.154

5.  Heterogeneity of Parkinson's disease.

Authors:  A Schrag; N P Quinn; Y Ben-Shlomo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

6.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

7.  Sex-related differences in olfactory function and evaluation of possible confounding factors among patients with Parkinson's disease.

Authors:  P Solla; C Masala; A Liscia; R Piras; T Ercoli; L Fadda; T Hummel; A Haenher; G Defazio
Journal:  J Neurol       Date:  2019-09-25       Impact factor: 4.849

8.  Health state values during the first year of drug treatment in early-stage Parkinson's disease: a prospective, population-based, cohort study.

Authors:  Corinna Vossius; Odd Bjarte Nilsen; Jan Petter Larsen
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

9.  An exploration of ocular fixation in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Authors:  Ralph Allen Pinnock; Richard Canice McGivern; Raeburn Forbes; James Mark Gibson
Journal:  J Neurol       Date:  2009-10-22       Impact factor: 4.849

10.  Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta.

Authors:  Rebecca L Cunningham; Andrea Giuffrida; James L Roberts
Journal:  Endocrinology       Date:  2009-10-16       Impact factor: 4.736
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.